Clinical Trial Update: A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

View source ↗

Summary

An update on a study investigating peripheral neuropathy associated with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Neoplasm | Status: ACTIVE_NOT_RECRUITING